All In Biotech

Drug Trial Radar · NCT00416520

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

336

Actual

Start

Jun 2007

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Dec 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.

Conditions

  • Chronic Kidney Disease
  • Hyperphosphatemia

Interventions

  • MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)Drug

    3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind

  • PlaceboDrug

    3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind

  • Another phosphate binder (Sevelamer)Drug

    Current approved dosing recommendations for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2)Time frame: week16 minus week12

Locations

68 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Adelaide, Australia

  • Site not named

    Nedlands, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    St Leonards, Australia

  • Site not named

    Sydney, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Frýdek-Místek, Czechia

  • Site not named

    HradecKralove, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Tábor, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Bordeaux, France

  • Site not named

    Montpelier, France

  • Site not named

    Paris, France

  • Site not named

    Aachen, Germany

  • Site not named

    Aschaffenburg, Germany

  • Site not named

    Coburg, Germany

  • Site not named

    Coesfeld, Germany

  • Site not named

    Darmstadt, Germany

  • Site not named

    Dieburg, Germany

  • Site not named

    Dortmund, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Homberg (Efze), Germany

  • Site not named

    Langen, Germany

  • Site not named

    Mannheim-Kafertal, Germany

  • Site not named

    München, Germany

  • Site not named

    Potsdam-Babelsberg, Germany

  • Site not named

    Baja, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Kisvárda, Hungary

  • Site not named

    Veszprém, Hungary

  • Site not named

    Biella, Italy

  • Site not named

    Como, Italy

  • Site not named

    Cremona, Italy

  • Site not named

    Lecco, Italy

  • Site not named

    Livorno, Italy

  • Site not named

    Milan, Italy

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.